期刊
ONCOTARGET
卷 7, 期 33, 页码 53571-53582出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.10670
关键词
HCC; liver cancer; SLC12A1; cancer outlier profile analysis; Bumetanide
资金
- National Natural Science Foundation of China [81470900, 81471585]
- Foundation of Shanghai Science and Technology Commission [15ZR1414100, 15411950403]
- Initiation Foundation For Young Scientist of Changzheng Hospital [2013CZQN05]
A central aim in cancer research is to identify genes with altered expression patterns in tumor specimens and their potential role in tumorigenesis. Most types of tumors, including hepatocellular carcinoma (HCC), are heterogeneous in terms of genotype and phenotype. Thus, traditional analytical methods like the t-test fail to identify all oncogenes from expression profiles. In this study, we performed a meta-Cancer Outlier Profile Analysis (meta-COPA) across six microarray datasets for HCC from the GEO database. We found that gene SLC12A1 was overexpressed in the Hep3B cell line, compared with five other HCC cell lines and L02 cells. We also found that the upregulation of SLC12A1 was mediated by histone methylation within its promoter region, and that SLC12A1 is a positive regulator of the WNK1/ERK5 pathway. Consistent with in vitro results, treatment with the SLC12A1 antagonist Bumetanide delayed tumor formation and reduced Hep3B cell tumor size in mouse xenografts. In summary, our research reveals a novel subset of HCCs that are sensitive to SLC12A1 antagonist treatment, thereby offering a new strategy for precision HCC treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据